DI NICOLANTONIO, Federica

DI NICOLANTONIO, Federica  

ONCOLOGIA  

Mostra records
Risultati 1 - 13 di 13 (tempo di esecuzione: 0.02 secondi).
Titolo Data di pubblicazione Autore(i) File
Abstract 1163: Microenvironment targets in KRAS-mutated metastatic colorectal cancer 2014 Marchio, Serena; Bartolini, Alice; Cardaci, Sabrina; Soster, Marco; Corti, Giorgio; Lamba, Simona; Bussolino, Federico; Cora', Davide; Di Nicolantonio, Federica
Acquired Resistance to Anti EGFR Therapy in Colorectal Cancer and Paracrine Protection by KRAS Mutated Cells 2012 Hobor S; Misale S; Crowley E; Scala E; Zanon C; Di Nicolantonio F; Bardelli A
BRAF V600E confers resistance to cetuximab or panitumumab metastatic colorectal cancer 2008 Di Nicolantonio F; Martini M; Molinari F; Bianchi AS; Arena S; Saletti P; Mazzucchelli L; Frattini M; Siena S; Bardelli A
Design and synthesis of encorafenib-based BRAF-V600E degraders 2022 Federica Blua, Marco Marino, Simone Gastaldi, Federica Maione, Eleonora Gianquinto, Federica Di Nicolantonio, Massimo Bertinaria
EMERGENCE OF KRAS MUTATIONS AND ACQUIRED RESISTANCE TO ANTI EGFR THERAPY IN COLORECTAL CANCER 2012 Misale S; Yaeger R; Hobor S; Scala E; Janakiraman M; Liska D; Valtorta E; Schiavo R; Buscarino M; Siravergna G; Bencardino K; Cercek A; Chen C; Veronese S; Zanon C; Sartore-Bianchi A; Gambacorta M; Gallicchio M; Vakiani E; Boscaro V; Medico E; Weiser M; Siena S; di Nicolantonio F; Solit D; Bardelli A
Fibroblast Growth Factor Receptor (FGFR)3 sustains acquired resistance to trastuzumab in gastric cancer patients 2015 Piro, Geny; Carbone, Carmine; Cataldo, Ivana; Di Nicolantonio, Federica; Giacopuzzi, Simone; Boschi, Federico; Zanotto, Marco; Merz, Valeria; Sbarbati, Andrea; De Manzoni, Giovanni; Scarpa, Aldo; Tortora, Giampaolo; Melisi, Davide
Isogenic K-Ras mutant cancer cells: A novel platform for drug profiling 2011 Goodall J; Hunt J; Chen Z; Di Nicolantonio F; Gallicchio M; Lamba S; Bardelli A; Mahoney C; Astley H; Torrance C; Grimshaw K
Knock in of cancer mutations in human cells predicts pharmacologicalresponse to targeted therapies 2011 Valentina Boscaro; Davide Zecchin; Federica Di Nicolantonio; Alberto Bardelli; Margherita Gallicchio
Knock-in of oncogenic mutations in human somatic cells as a tool to identify genoselective compounds 2007 Federica Di Nicolantonio; Sabrina Arena; Margherita Gallicchio; Miriam Martini; Davide Zecchin; Simona Flonta; Giulia Stella; Giovanni Appendino; Roberto Fantozzi; Enzo Medico; Alberto Bardelli
RAF Inhibitors 2011 Di Nicolantonio F
Rapid up-regulation of cyclo-oxygenase 2 (COX-2) by 5-fluoruracil (5-FU) in human solid tumours 2004 Di Nicolantonio F; Mercer S; Knight LA; Gabriel FG; Whitehouse PA; Sharma S; Fernando A; Bhandari P; Somers SS; Toh SK; Cree IA
Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells 2019 Amodio, V; Grmano, G; Barault, L; Lamba, S; Rospo, G; Magri, A; Maione, F; Crisafulli, G; Cancelliere, C; Lerda, G; Bartolini, A; Siravegna, G; Mussolin, B; Frappolli, R; Montone, M; Randon, G; de Braud, F; Angelozzi, NA; Marsoni, S; D'Incalci, M; Orlandi, A; Giraudo, E; Satore-Bianchi, A; Siena, S; Pietrantonio, F; Di Nicolantonio, F; Bardelli, A
Unveiling of BRAF V600E Mutant Cells Sensitivity to Proteasome Inhibitors Using an Isogenic Cell Based Screening 2013 V. Boscaro; D. Zecchin; A. Bardelli; F. Di Nicolantonio; M. Gallicchio